- Home
- BBIO vs ESAB Comparison
BBIO vs ESAB Comparison
Compare BBIO & ESAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBIO
- ESAB
- Stock Information
- Founded
- BBIO 2015
- ESAB 1904
- Country
- BBIO United States
- ESAB United States
- Employees
- BBIO N/A
- ESAB N/A
- Industry
- BBIO Biotechnology: Pharmaceutical Preparations
- ESAB Office Equipment/Supplies/Services
- Sector
- BBIO Health Care
- ESAB Industrials
- Exchange
- BBIO Nasdaq
- ESAB Nasdaq
- Market Cap
- BBIO 6.7B
- ESAB 6.9B
- IPO Year
- BBIO 2019
- ESAB N/A
- Fundamental
- Price
- BBIO $34.17
- ESAB $127.83
- Analyst Decision
- BBIO Strong Buy
- ESAB Buy
- Analyst Count
- BBIO 12
- ESAB 8
- Target Price
- BBIO $57.09
- ESAB $136.13
- AVG Volume (30 Days)
- BBIO 3.1M
- ESAB 270.9K
- Earning Date
- BBIO 04-29-2025
- ESAB 05-01-2025
- Dividend Yield
- BBIO N/A
- ESAB 0.25%
- EPS Growth
- BBIO N/A
- ESAB 16.34
- EPS
- BBIO N/A
- ESAB 4.43
- Revenue
- BBIO $127,415,000.00
- ESAB $2,729,197,000.00
- Revenue This Year
- BBIO $13.67
- ESAB N/A
- Revenue Next Year
- BBIO $118.02
- ESAB $5.05
- P/E Ratio
- BBIO N/A
- ESAB $28.60
- Revenue Growth
- BBIO N/A
- ESAB N/A
- 52 Week Low
- BBIO $21.62
- ESAB $88.54
- 52 Week High
- BBIO $39.47
- ESAB $135.97
- Technical
- Relative Strength Index (RSI)
- BBIO 44.19
- ESAB 63.88
- Support Level
- BBIO $33.92
- ESAB $120.56
- Resistance Level
- BBIO $39.16
- ESAB $124.96
- Average True Range (ATR)
- BBIO 1.50
- ESAB 3.98
- MACD
- BBIO -0.24
- ESAB 1.19
- Stochastic Oscillator
- BBIO 10.35
- ESAB 95.83
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
About ESAB ESAB Corporation
ESAB, spun off from Colfax in 2022, is a leading manufacturer of equipment and consumables used in welding, cutting, and joining applications. Alongside competitors Lincoln Electric and ITW's Miller brand, ESAB is one of the top three players in the welding space. ESAB generated roughly $2.7 billion in revenue in 2024.